Surgical oncology device maker Onkos Surgical today filed an amendment to an SEC Form D confirming the sale of $26.5 million in equity.
The equity offering had its first sale on Aug. 31, 2021 and today reached $26,500,001. That leaves no amount remaining to be sold.
According to the amended SEC Form D, 16 investors participated in the fundraising, which had no minimum investment amount for outside investors.
Onkos said in the filing that the fundraising was not made in connection with a business combination transaction, such as a merger, acquisition or exchange offer.
In April 2020, Onkos confirmed the sale of nearly $7.6 million in equity. The Parsippany, New Jersey-based company’s total offering amount in that instance was $12 million. That financing was intended to add the $12 million total to a $17.6 million Series B funding round that Onkos closed in 2017.
The company develops a range of devices, including the BioGrip 3D-printed implant for aseptic loosening in musculoskeletal oncology and complex orthopedic limb salvage surgery and the Eleos Proximal Tibia with BioGrip technology for use in complex tumor and orthopedic reconstructive procedures.
Earlier this week, Onkos announced that it agreed to acquire the Juvenile Tumour System (JTS) from Stryker (NYSE:SYK). The system is designed to enable limb stabilization and growth in pediatric patients affected by bone cancers, severe arthropathy, severe trauma, revisions, oncology and malignant diseases.
